Want to see IN:ALBERTDAVD full AI Analyst Report?
Top Page
Albert David Ltd
(ALBERTDAVD)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹828.00
▲(5.02% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weakened fundamentals—profitability has slipped into loss territory and operating/free cash flow turned negative in 2025–2026—despite a conservatively financed balance sheet. Technicals are supportive with strong momentum and price above major moving averages, but the elevated RSI signals the move may be stretched. Valuation appears moderate on P/E with a low dividend yield.
Positive Factors
Conservative Balance Sheet
Low leverage reduces financial strain and preserves borrowing capacity. This provides resilience while the company addresses weaker earnings and cash generation, supporting continuity of pharmaceutical operations over the medium term.
Negative Factors
Recent Net Loss
The shift from solid profits to a loss signals that the current business base is not producing dependable bottom-line earnings. Persistent losses could weaken reinvestment capacity and reduce the benefit of the company’s strong balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage reduces financial strain and preserves borrowing capacity. This provides resilience while the company addresses weaker earnings and cash generation, supporting continuity of pharmaceutical operations over the medium term.
Read all positive factors
Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.61B
Dividend Yield0.61%
Average Volume (3M)210.00
Price to Earnings (P/E)20.5
Beta (1Y)1.13
Revenue Growth11.43%
EPS Growth258.53%
CountryIN
Employees1,476
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)39.54
Shares Outstanding5,707,162
10 Day Avg. Volume184
30 Day Avg. Volume210
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)0.86
Price to Sales (P/S)1.00
P/FCF Ratio-9.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Albert David Ltd Business Overview & Revenue Model
Company Description
Albert David Limited is an Indian pharmaceutical company specializing in the production and distribution of a diverse array of medical products. Its offerings encompass pharmaceutical formulations, intravenous solutions, herbal medicines, bulk dru...
How the Company Makes Money
Albert David Ltd primarily makes money by selling pharmaceutical products it manufactures and/or markets. Key revenue streams include: (1) Domestic sales of finished-dose formulations (e.g., tablets, capsules, syrups/other dosage forms) to hospita...
Albert David Ltd Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.64B | 3.34B | 3.46B | 3.60B | 3.42B | 3.12B |
| Gross Profit | 1.30B | 1.07B | 2.29B | 2.32B | 2.18B | 1.95B |
| EBITDA | -2.27M | 129.20M | 30.26M | 1.05B | 598.68M | 567.76M |
| Net Income | 225.66M | -14.95M | 172.01M | 754.20M | 361.75M | 352.58M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.19B | 5.11B | 4.98B | 4.23B | 4.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.58B | 2.58B | 2.44B | 2.85B | 2.03B | 1.75B |
| Total Debt | 0.00 | 297.11M | 123.17M | 33.24M | 53.18M | 56.62M |
| Total Liabilities | -3.92B | 1.28B | 1.19B | 1.15B | 1.12B | 1.23B |
| Stockholders Equity | 3.92B | 3.92B | 3.92B | 3.83B | 3.12B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | -271.21M | -350.95M | -432.92M | 346.28M | 52.78M | 292.83M |
| Operating Cash Flow | -208.45M | -59.83M | -284.36M | 455.02M | 105.15M | 403.65M |
| Investing Cash Flow | -46.97M | -85.53M | 233.01M | -332.48M | -49.95M | -396.97M |
| Financing Cash Flow | 248.82M | 144.00M | 1.10M | -82.70M | -63.62M | -12.59M |
Albert David Ltd Technical Analysis
Positive
788.40
Price Trends
709.41
Positive
707.09
Positive
725.25
Positive
Market Momentum
28.52
Negative
73.90
Negative
63.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Positive. The current price of 788.4 is above the 20-day moving average (MA) of 723.45, above the 50-day MA of 709.41, and above the 200-day MA of 725.25, indicating a bullish trend. The MACD of 28.52 indicates Negative momentum. The RSI at 73.90 is Negative, neither overbought nor oversold. The STOCH value of 63.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALBERTDAVD.
Albert David Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹48.53B | 28.95 | ― | 0.97% | 18.56% | 60.06% | |
63 Neutral | ₹439.76B | 38.55 | ― | 0.23% | 10.59% | 68.21% | |
62 Neutral | ₹163.38B | 23.57 | ― | 1.38% | 14.12% | 14.98% | |
60 Neutral | ₹660.35B | 36.39 | ― | 0.24% | 32.94% | 138.54% | |
57 Neutral | ₹37.93B | 12.48 | ― | ― | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.61B | 20.55 | ― | 0.66% | 11.43% | 258.53% |
* General Sector Average
IN:ALBERTDAVD
Albert David Ltd
807.70
5.78
0.72%
IN:APLLTD
Alembic Pharmaceuticals Limited
831.20
-127.83
-13.33%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,340.00
370.43
18.81%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
165.35
72.41
77.91%
IN:IPCALAB
IPCA Laboratories Limited
1,733.65
353.74
25.64%
IN:UNICHEMLAB
Unichem Laboratories Limited
538.80
29.00
5.69%
Albert David Ltd Corporate Events
Albert David publishes Q1 FY2026 unaudited results in newspapers
Aug 7, 2026
Albert David Ltd has notified the stock exchanges that it has published extracts of its unaudited financial results for the first quarter ended June 30, 2026 in national and regional newspapers. The disclosure, made in compliance with SEBI’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.